Loading clinical trials...
Loading clinical trials...
Randomized, Phase II Trial of Atorvastatin, RAFTILOSE Synergy 1, and Sulindac Among Patients at Increased Risk for Sporadic Colorectal Neoplasia
Conditions
Interventions
oligofructose-enriched inulin
sulindac
+3 more
Locations
1
United States
Mayo Clinic
Rochester, Minnesota, United States
Start Date
March 1, 2006
Primary Completion Date
April 1, 2009
Completion Date
April 1, 2009
Last Updated
February 15, 2017
NCT04704661
NCT06696768
NCT04929028
NCT05489211
NCT06625775
NCT04657068
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions